# CHFR Methylation Status Esophageal Cancer Study

> **NCT01372202** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 31 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **RADIATION:** Radiotherapy
- **PROCEDURE:** Esophagectomy

## Key facts

- **NCT ID:** NCT01372202
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-10-01
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study stopped due to early stopping rule
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01372202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01372202, "CHFR Methylation Status Esophageal Cancer Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01372202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*